TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28642554

Group type: EXPERIMENTAL
Intervention: YouTube video intervention
Number of subjects: 67

Group type: COMPARATOR
Intervention: Standard verbal and written information (Control)
Number of subjects: 67
Study: 25153249

Group type: EXPERIMENTAL
Intervention: Polaris stent
Number of subjects: 144

Group type: COMPARATOR
Intervention: Percuflex stent
Number of subjects: 144
Study: 23306596

Group type: EXPERIMENTAL
Intervention: Incredible Years Toddler Parenting Program (12 sessions)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Incredible Years Toddler Parenting Program (12 sessions) under research contexts (with weekly supervision)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Incredible Years Toddler Parenting Program with London cost weighting
Number of subjects: 0
Study: 20833991

Group type: EXPERIMENTAL
Intervention: Almond-enriched ADA diet (20% of energy from almonds, approximately 2 oz per day)
Number of subjects: 65
Study: 18947487

Group type: EXPERIMENTAL
Intervention: GOS-formula feeding (2.4 g/L)
Number of subjects: 371

Group type: EXPERIMENTAL
Intervention: Human milk
Number of subjects: 371

Group type: COMPARATOR
Intervention: Formula feeding without GOS
Number of subjects: 371
Study: 15843764

Group type: EXPERIMENTAL
Intervention: Reboxetine at a dose of 4 mg/day
Number of subjects: 31
Study: 12592082

Group type: EXPERIMENTAL
Intervention: Bexarotene (oral or topical gel)
Number of subjects: 10
Study: 10470423

Group type: EXPERIMENTAL
Intervention: 5-FU 450 mg/m2 plus Levamisol (B)
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: 5-FU 600 mg/m2 (C)
Number of subjects: 187

Group type: COMPARATOR
Intervention: Observation only (A)
Number of subjects: 187
Study: 8767614

Group type: EXPERIMENTAL
Intervention: Propafenone 450 mg as single dose followed by 300 mg t.i.d.
Number of subjects: 80

Group type: COMPARATOR
Intervention: Hydroquinidine 900 mg/24 hours + digoxin if necessary
Number of subjects: 80
Study: 1826073

Group type: EXPERIMENTAL
Intervention: 30 micrograms sufentanil (group A)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 5 mg morphine (group B)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 30 micrograms sufentanil plus 3 mg morphine (group C)
Number of subjects: 45
Study: 6991534

Group type: EXPERIMENTAL
Intervention: Aspirin (1000 mg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Aspirin (500 mg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Codeine (30 mg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Proquazone (300 mg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: New formulations of analgesic combinations (aminophenazone replaced by propyphenazone)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Aspirin (250 mg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30

Group type: COMPARATOR
Intervention: Aspirin (1000 mg) vs Placebo
Number of subjects: 30
Study: 30589607

Group type: EXPERIMENTAL
Intervention: Salbutamol nebulization (5 mg)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo nebulization (saline volume equivalent)
Number of subjects: 43
Study: 28222149

Group type: EXPERIMENTAL
Intervention: Praziquantel treatment (20, 40, and 60 mg/kg)
Number of subjects: 283

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 283
Study: 25887550

Group type: EXPERIMENTAL
Intervention: Multimodal treatment (MMT) including neurophysiological education, sensory training, and motor training, with up to 16 sessions over 8 to 12 weeks and additional home training of 10 to 30 minutes five times per week.
Number of subjects: 28

Group type: COMPARATOR
Intervention: Usual physiotherapy treatment (UPT), with up to 16 sessions over 8 to 12 weeks and additional home training of 10 to 30 minutes five times per week.
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Multimodal treatment (MMT)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Usual physiotherapy treatment (UPT)
Number of subjects: 28
Study: 24014982

Group type: EXPERIMENTAL
Intervention: Diffractive multifocal IOL
Number of subjects: 25

Group type: COMPARATOR
Intervention: Pseudo-accommodative IOL
Number of subjects: 25
Study: 21382958

Group type: EXPERIMENTAL
Intervention: Polarity Therapy (PT)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Modified Massage
Number of subjects: 45

Group type: COMPARATOR
Intervention: Standard Care
Number of subjects: 45
Study: 19636365

Group type: EXPERIMENTAL
Intervention: Pentavalent antimony plus 5% imiquimod cream applied to each lesion three times per week for 20 days
Number of subjects: 80

Group type: COMPARATOR
Intervention: Pentavalent antimony plus placebo (vehicle cream) applied as above
Number of subjects: 80
Study: 16454145

Group type: EXPERIMENTAL
Intervention: Zinc gluconate nasal spray (10 mmol)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study: 15281969

Group type: EXPERIMENTAL
Intervention: Selective laser trabeculoplasty (SLT)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Medical treatment
Number of subjects: 29
Study: 11410114

Group type: EXPERIMENTAL
Intervention: Lisinopril 20 mg for 8 weeks
Number of subjects: 23
Study: 9241569

Group type: EXPERIMENTAL
Intervention: Brofaromine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Imipramine
Number of subjects: 0
Study: 7686216

Group type: COMPARATOR
Intervention: Cisplatin 100 mg/m2 IV day 1 and Vinblastine 6 mg/m2 IV days 1 and 2 every 3 weeks (PV)
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Cisplatin 100 mg/m2 IV day 1 and Vinblastine 6 mg/m2 IV days 1 and 2 every 3 weeks with Bleomycin 30 mg IM weekly (PVB)
Number of subjects: 218

Group type: COMPARATOR
Intervention: PV
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: PVB
Number of subjects: 218
Study: 3575424

Group type: EXPERIMENTAL
Intervention: Static stretch and ultrasound (SS and US)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Static stretch (SS)
Number of subjects: 30

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 30
Study: 29356899

Group type: EXPERIMENTAL
Intervention: Mindfulness training program (MAP)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Structured psychoeducation (PE)
Number of subjects: 81
Study: 26630538

Group type: EXPERIMENTAL
Intervention: Levonorgestrel-impregnated intrauterine system (LNG‐IUS)
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: 10 mg of oral medroxyprogesterone acetate (MPA) administered for 10 days per cycle for 6 months
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: 10 mg of oral medroxyprogesterone acetate (MPA) administered daily for 6 months
Number of subjects: 153
Study: 24152323

Group type: EXPERIMENTAL
Intervention: Closed-loop (CL) system with predictive rule-based algorithm (pRBA)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Open-loop (OL) system
Number of subjects: 10
Study: 22134043

Group type: EXPERIMENTAL
Intervention: Olanzapine (5‐20 mg/day)
Number of subjects: 224

Group type: COMPARATOR
Intervention: Haloperidol (2.5‐10 mg/day)
Number of subjects: 224

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 224
Study: 20507374

Group type: EXPERIMENTAL
Intervention: New dentifrice containing zinc‐carbonate hydroxyapatite (CHA) nanocrystals
Number of subjects: 70

Group type: COMPARATOR
Intervention: Potassium nitrate/fluoride dentifrice (active control)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Both dentifrices
Number of subjects: 70
Study: 16708310

Group type: EXPERIMENTAL
Intervention: Diagnostic tests (CRP, leucocyte count, rapid Strep A, chest X-ray, sinus X-ray, throat culture)
Number of subjects: 1108

Group type: EXPERIMENTAL
Intervention: CRP test (above 50 mg/l)
Number of subjects: 1108

Group type: EXPERIMENTAL
Intervention: Leucocyte count (above 10,000/microl)
Number of subjects: 1108

Group type: EXPERIMENTAL
Intervention: Positive Strep A test
Number of subjects: 1108

Group type: EXPERIMENTAL
Intervention: Diagnostic tests
Number of subjects: 1108
Study: 11356731

Group type: EXPERIMENTAL
Intervention: Nystatin + diet (ND)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Placebo + diet (PD)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Nystatin (N)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 116
Study: 9135240

Group type: EXPERIMENTAL
Intervention: Single latex gloves
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Double latex gloves
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Simple Kevlar glove with latex inside and outside
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Kevlar and Medak glove with latex inside and outside
Number of subjects: 25

Group type: COMPARATOR
Intervention: No gloves
Number of subjects: 25
Study: 7525692

Group type: EXPERIMENTAL
Intervention: IgG anti‐HCVcore
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: IgM anti‐HCVcore
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Viremic levels
Number of subjects: 71

Group type: COMPARATOR
Intervention: Correlation of IgM anti‐HCVcore
Number of subjects: 71
Study: 3654485

Group type: EXPERIMENTAL
Intervention: High level of teacher intrusion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low level of teacher intrusion
Number of subjects: 0
Study: 29804268

Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Number of subjects: 149

Group type: COMPARATOR
Intervention: Best Available Therapy (BAT)
Number of subjects: 149
Study: 27448051

Group type: EXPERIMENTAL
Intervention: Narrow-band imaging (NBI)
Number of subjects: 380

Group type: COMPARATOR
Intervention: High-definition white light (HDWL)
Number of subjects: 380
Study: 25522395

Group type: EXPERIMENTAL
Intervention: 24 IU intranasal oxytocin
Number of subjects: 15
Study: 22808045

Group type: EXPERIMENTAL
Intervention: Heated blood transfusion/fluid infusion
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Body wrapping and heating blanket
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Body wrapping, heated moist dressings, and heating blanket
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Body wrapping, heated moist dressings, and warmed surgical rinse fluid
Number of subjects: 160

Group type: COMPARATOR
Intervention: Control (not receiving warming methods)
Number of subjects: 160
Study: 20479297

Group type: EXPERIMENTAL
Intervention: Etanercept, 50 mg, SC administered twice weekly for 12 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 18184958

Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy
Number of subjects: 537

Group type: COMPARATOR
Intervention: Conventional insulin therapy
Number of subjects: 537

Group type: EXPERIMENTAL
Intervention: HES therapy
Number of subjects: 537

Group type: COMPARATOR
Intervention: Ringer's lactate
Number of subjects: 537
Study: 15844469

Group type: EXPERIMENTAL
Intervention: DHEA replacement (50 mg/day)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study: 15318461

Group type: COMPARATOR
Intervention: Saline 0.9%
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Low-dose remifentanil (1 microg kg(‐1))
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: High-dose remifentanil (3 microg kg(‐1))
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Remifentanil (any dose)
Number of subjects: 54
Study: 11386092

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.2%
Number of subjects: 28

Group type: COMPARATOR
Intervention: Bupivacaine 0.125% plus 0.5 microgram ml‐1 sufentanil
Number of subjects: 28
Study: 9225534

Group type: EXPERIMENTAL
Intervention: Test dentifrice containing 500ppm NaF plus 500ppm NaMFP
Number of subjects: 1633

Group type: COMPARATOR
Intervention: Control product containing 1000ppm NaMFP
Number of subjects: 1633
Study: 8128328

Group type: EXPERIMENTAL
Intervention: Endoscopic thrombin injections in actively bleeding patients (group II, N = 94)
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Endoscopic thrombin injections in non-bleeding visible vessels (group A, N = 25)
Number of subjects: 191

Group type: COMPARATOR
Intervention: Conventional management in actively bleeding patients (group I, N = 47)
Number of subjects: 191

Group type: COMPARATOR
Intervention: No primary endoscopic treatment in non-bleeding visible vessels (group B, N = 25)
Number of subjects: 191
Study: 3325472

Group type: EXPERIMENTAL
Intervention: Pili canaliculi hair abnormality
Number of subjects: 0
Study: 30593081

Group type: EXPERIMENTAL
Intervention: Updated Birth Score (score range 0 to 86)
Number of subjects: 121640

Group type: COMPARATOR
Intervention: Current Birth Score
Number of subjects: 121640
Study: 29472134

Group type: EXPERIMENTAL
Intervention: Single tDCS (7-min)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Double tDCS (7-min and 5-min separated by 3-min rest)
Number of subjects: 75
Study: 26731401

Group type: EXPERIMENTAL
Intervention: Supportive short message services (SMS) sent to HSAs during a 12-month period, including motivational and data quality SMS.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Motivational SMS only (control group).
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparison between treatment and control groups during the intervention period.
Number of subjects: 0
Study: 25049135

Group type: EXPERIMENTAL
Intervention: 6% whey protein isolate drink (528 kJ) (PRO)
Number of subjects: 12

Group type: COMPARATOR
Intervention: low energy placebo (15 kJ) (PLA)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 6% sucrose drink (528 kJ) (CHO)
Number of subjects: 12
Study: 22664664

Group type: EXPERIMENTAL
Intervention: Informative ISA
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Incentive ISA
Number of subjects: 153

Group type: COMPARATOR
Intervention: ISA turned off
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: PAYS concept
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: ISA on rural roads
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Mean free flow speed and 85th percentile speed
Number of subjects: 153
Study: 20346780

Group type: EXPERIMENTAL
Intervention: bimatoprost 0.01%
Number of subjects: 561

Group type: EXPERIMENTAL
Intervention: bimatoprost 0.0125%
Number of subjects: 561

Group type: COMPARATOR
Intervention: bimatoprost 0.03%
Number of subjects: 561
Study: 17654740

Group type: EXPERIMENTAL
Intervention: Caucasian patients with PBC
Number of subjects: 535

Group type: COMPARATOR
Intervention: Non-Caucasian patients with PBC
Number of subjects: 535

Group type: EXPERIMENTAL
Intervention: Non-Caucasian patients (African American and Hispanic)
Number of subjects: 535

Group type: EXPERIMENTAL
Intervention: Caucasian and Non-Caucasian patients
Number of subjects: 535
Study: 15804195

Group type: EXPERIMENTAL
Intervention: Abuse-prevention curriculum designed to empower women with mental retardation
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Both groups (intervention and control)
Number of subjects: 36
Study: 12572380

Group type: EXPERIMENTAL
Intervention: Qinghuo Baidu Yin (QHBDY)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Conventional therapy + QHBDY
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 30
Study: 9794854

Group type: EXPERIMENTAL
Intervention: Statistical methods for cost data
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Health economic evaluations
Number of subjects: 45
Study: 8556909

Group type: EXPERIMENTAL
Intervention: Mifepristone 150 mg single dose treatment
Number of subjects: 24

Group type: COMPARATOR
Intervention: Early pregnant cervix before treatment
Number of subjects: 24
Study: 2242521

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Nifedipine-ISDN combination
Number of subjects: 28

Group type: COMPARATOR
Intervention: Isosorbide dinitrate (ISDN)
Number of subjects: 28
Study: 577428

Group type: EXPERIMENTAL
Intervention: Benzopyrone compound Venalot (2 depot tablets b.d.)
Number of subjects: 0
Study: 29733117

Group type: EXPERIMENTAL
Intervention: Exercise + active phototherapy (nine‐diode cluster device: one 905 nm super‐pulsed diode laser, four 875 nm LED and four 640 nm LED; energy per quadrant: 7.85 J; total energy: 23.55 J per session)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Exercise + active phototherapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Exercise alone
Number of subjects: 60

Group type: COMPARATOR
Intervention: Exercise + placebo phototherapy
Number of subjects: 60
Study: 27314841

Group type: EXPERIMENTAL
Intervention: BiOSS Expert® (paclitaxel)
Number of subjects: 34

Group type: COMPARATOR
Intervention: BiOSS LIM® (sirolimus)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Final kissing balloon/proximal optimization technique (FKB/POT)
Number of subjects: 34
Study: 25012399

Group type: EXPERIMENTAL
Intervention: Cognitive bias modification (CBM) intervention delivered via the internet over a period of 52 weeks
Number of subjects: 532

Group type: EXPERIMENTAL
Intervention: Cognitive bias modification (CBM) intervention
Number of subjects: 532

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 532
Study: 22268971

Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Whole-body vibration plus localized radiofrequency (WBV+RF)
Number of subjects: 44
Study: 20563469

Group type: EXPERIMENTAL
Intervention: Modified ultrafiltration (MUF)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control (no MUF)
Number of subjects: 37
Study: 19014751

Group type: EXPERIMENTAL
Intervention: Olanzapine (5‐20 mg/day)
Number of subjects: 521

Group type: EXPERIMENTAL
Intervention: Divalproex (500‐2500 mg/day)
Number of subjects: 521

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 521
Study: 16292090

Group type: EXPERIMENTAL
Intervention: S. boulardii 500 mg twice daily
Number of subjects: 389

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 389
Study: 12785003

Group type: EXPERIMENTAL
Intervention: Adenosine infusion (40 microg/kg/min)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo infusion (saline)
Number of subjects: 21
Study: 10596504

Group type: EXPERIMENTAL
Intervention: Behaviorally based parenting skills classes
Number of subjects: 303

Group type: COMPARATOR
Intervention: Wait-list condition
Number of subjects: 303
Study: 8692554

Group type: EXPERIMENTAL
Intervention: Metoclopramide plus dexamethasone and diphenhydramine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ondansetron plus dexamethasone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Metoclopramide plus methylprednisolone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Metoclopramide and dexamethasone plus diphenhydramine
Number of subjects: 0
Study: 1667753

Group type: EXPERIMENTAL
Intervention: Pyrophosphate dentifrice (F-Antibelag Gel + K4P2O7/Na4P2O7)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (F-Antibelag Gel)
Number of subjects: 60
Study: 7068078

Group type: EXPERIMENTAL
Intervention: Essaven ultra
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 31262153

Group type: EXPERIMENTAL
Intervention: Maximal strength training (twice a week for 3 months)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control group (prescribed treatment without strength training)
Number of subjects: 55
Study: 28600624

Group type: EXPERIMENTAL
Intervention: N2O/2
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: N2O/4
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: N2O/6
Number of subjects: 78

Group type: COMPARATOR
Intervention: O2/air groups
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: AGC performance
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Wash-in speeds
Number of subjects: 78
Study: 27624485

Group type: EXPERIMENTAL
Intervention: Patient training programme including detailed information on their condition and practical training in using a portable blood coagulation monitor.
Number of subjects: 333

Group type: EXPERIMENTAL
Intervention: Patient training programme
Number of subjects: 333

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 333
Study: 24623024

Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy (IT) with a target blood glucose range of 4.4‐6.1 mmol/L
Number of subjects: 447

Group type: COMPARATOR
Intervention: Intermediate insulin therapy (IT) with a target blood glucose range of 7.7‐10.0 mmol/L
Number of subjects: 447

Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy (IT)
Number of subjects: 447
Study: 22278087

Group type: EXPERIMENTAL
Intervention: AF-CBT training (n = 90)
Number of subjects: 182

Group type: COMPARATOR
Intervention: Training as Usual (TAU; n = 92)
Number of subjects: 182
Study: 20227728

Group type: EXPERIMENTAL
Intervention: Polyethylene caps
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Polyethylene occlusive skin wrap
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control (conventional drying)
Number of subjects: 96
Study: 17941876

Group type: COMPARATOR
Intervention: Nateglinide monotherapy (120 mg before meals)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Nateglinide (120 mg before meals) + Metformin (up to 1000 mg bid)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Glyburide (up to 5 mg bid) + Metformin (up to 1000 mg bid)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Nateglinide + Metformin
Number of subjects: 135
Study: 15699447

Group type: EXPERIMENTAL
Intervention: Endurance exercise training (3 months jogging)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (no exercise training)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Endurance exercise training
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 31
Study: 12802092

Group type: EXPERIMENTAL
Intervention: Standard tongue strength exercises using a tongue depressor
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Tongue strengthening exercises using the Iowa Oral Performance Instrument
Number of subjects: 31

Group type: COMPARATOR
Intervention: No exercise
Number of subjects: 31
Study: 11105936

Group type: EXPERIMENTAL
Intervention: Cocaine (0.9 mg/kg)
Number of subjects: 18
Study: 9065557

Group type: EXPERIMENTAL
Intervention: Hu-related molecules of 35 to 41 kDa detected in the membrane of small-cell lung cancers and neuroblastomas using immunofluorescence, absorption assays, Western blotting on membrane fractions, and surface biotinylation.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Detection of Hu-related antigens in the nucleus and membrane of small-cell lung cancer and neuroblastomas.
Number of subjects: 0
Study: 8452191

Group type: EXPERIMENTAL
Intervention: Fleroxacin 400 mg
Number of subjects: 289

Group type: COMPARATOR
Intervention: Amoxicillin 3,000 mg
Number of subjects: 289
Study: 2878173

Group type: EXPERIMENTAL
Intervention: Warfarin started within 3 days of heparin (group S)
Number of subjects: 266

Group type: COMPARATOR
Intervention: Warfarin started after 7 days of heparin (group L)
Number of subjects: 266